Catalyst Dossier · compiled by CeliA 🧫

WUXI (WXI)

Healthcare · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-12-15 (est.)Phase 3 · Mesenchymal Stem Cellsimp 9/10
2026-12-31 (est.)Otherimp 3/10
2027-04-15 (est.)Phase 2 · D3S-001imp 7/10
2027-05-30 (est.)Phase 2 · NWRD08 administered by electroporationimp 7/10

Pipeline

Asset	Phase	Indication
5 mg BGM0504 injection	Phase 3	Overweight or Obesity
Guideline-directed medical therapy (GDMT) for heart failure	Phase 3	Pulmonary Hypertension
Mesenchymal Stem Cells	Phase 3	Knee Osteoarthritis
CU-20101 treatment for Moderate to Severe Glabellar Striae	Phase 3	Glabellar Frown Lines
CU-40102 Spray	Phase 3	AGA
D3S-001	Phase 2	KRAS P.G12C
CU-20401	Phase 2	Safety
Subcutaneous injection of CU-20401	Phase 2	Efficacy and Safety
Lidocaine tetracaine cream	Phase 3	Analgesia
D3S-002	Phase 2	Advanced Solid Tumors With MAPK Pathway Mutations
NWRD08 administered by electroporation	Phase 2	High-grade Squamous Intraepithelial Lesion (HSIL)

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for WXI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.